Quote | Lixte Biotechnology Holdings Inc. Warrants (NASDAQ:LIXTW)
Last: | $0.0597 |
---|---|
Change Percent: | -6.03% |
Open: | $0.0633 |
Close: | $0.0597 |
High: | $0.0633 |
Low: | $0.0597 |
Volume: | 599 |
Last Trade Date Time: | 06/28/2024 03:00:00 am |
News | Lixte Biotechnology Holdings Inc. Warrants (NASDAQ:LIXTW)
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ...
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ȁ...
Message Board Posts | Lixte Biotechnology Holdings Inc. Warrants (NASDAQ:LIXTW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Lixte Biotechnology Holdings Inc. Warrants Company Name:
LIXTW Stock Symbol:
NASDAQ Market:
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ...
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ȁ...
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( ...